Public Production of Medicines: Contribution to Health Autonomy in Colombia
DOI:
https://doi.org/10.17533/udea.vitae.v33n1a364050Downloads
References
González Rodríguez AL, Cataño Rocha CE, Ospina de Barreneche N, Bedoya Salazar A, Agudelo Torres E. Más de un siglo de historia: de Escuela de Farmacia a Facultad de Ciencias Farmacéuticas y Alimentarias, 1915–2017 [Internet]. 1st ed. Medellín: Universidad de Antioquia; 2018. ISBN: 978-958-5526-08-2. Available from: https://www.udea.edu.co/wps/wcm/connect/udea/c7ddb769-1464-450a-a522-696ea4f5f8e0/Mas+de+un+siglo+de+historia_ebook_compressed.pdf?MOD=AJPERES&CVID=p4Fih5V
Universidad de Antioquia. Planta de Producción de Medicamentos Esenciales UdeA fue recertificada en buenas prácticas. UdeA Noticias. 2022 Jul 15. Available from: https://www.udea.edu.co/wps/portal/udea/web/inicio/udea-noticias/udea-noticia/!ut/p/z0/fYwxD4IwFIT_igujebVi1ZE4mBgHB2Ogi3nSqg-hD2gx_nwBB-Pi8uXucnegIQXt8Ek3DMQOy95nWp1X642cJbHYCxUrkahDvFjK7fx4ErAD_b_QP1DRNDoBnbML9hUgrbkNWHbGYiTQ_7o7V_ajB04cB8oJfSTGtSPDQ-sbe87JGjSRuOKlpRwra0a6wH5adCWxlFA_dPYGu6addQ!!/
Universidad de Antioquia. Con recursos asegurados, UdeA proyecta nueva sede para su Planta de Medicamentos Esenciales. UdeA Noticias. 2026 Feb 13. Available from: https://www.udea.edu.co/wps/portal/udea/web/inicio/udea-noticias/udea-noticia/Contenido/asNoticias/Academia/nuevo-convenio-planta-de-medicamentos
El Periódico El Oriente. Nueva planta de medicamentos de la UdeA en El Carmen de Viboral. 2026 Jan 10. Available from: https://periodicoeloriente.co/el-carmen-de-viboral-sera-la-sede-de-la-megaplanta-de-medicamentos-de-la-udea/
Congreso de Colombia. Ley 2386 de 2024. Política Nacional de Investigación Científica, Desarrollo Tecnológico, Innovación y Producción de la Industria Farmacéutica para la Autonomía Sanitaria [Internet]. Bogotá: Diario Oficial; 2024 [cited 2026 Feb 19]. Available from: https://www.suin-juriscol.gov.co/viewDocument.asp?ruta=Leyes/30052895
Ministerio de Ciencia, Tecnología e Innovación. Resolución 1452 de 2024. Políticas de Investigación e Innovación Orientadas por Misiones (PIIOM) [Internet]. Bogotá: MinCiencias; 2024 [cited 2026 Feb 19]. Available from: https://minciencias.gov.co/normatividad/resolucion-1452-2024
República de Colombia. Consejo Nacional de Política Económica y Social. Departamento Nacional de Planeación. Documento CONPES 4129: Política Nacional de Reindustrialización. Bogotá: DNP; 2023. Available from: https://colaboracion.dnp.gov.co/CDT/Conpes/Econ%C3%B3micos/4129.pdf
República de Colombia. Consejo Nacional de Política Económica y Social. Documento CONPES 4170: Fortalecimiento de la producción nacional de productos farmacéuticos que garanticen la soberanía sanitaria nacional [Internet]. Bogotá: Departamento Nacional de Planeación (DNP); 2025 [cited 2026 Feb 19]. Available from: https://colaboracion.dnp.gov.co/CDT/Conpes/Econ%C3%B3micos/4170.pdf
Congreso de Colombia. Ley Estatutaria 1751 de 2015 [Internet]. Bogotá: Diario Oficial; 2015 [cited 2026 Feb 19]. Available from: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=60733
Calderón E, Tapias JA, Barreto DM. ¿Soberanía farmacéutica en Colombia? Con-Texto [Internet]. 2021;55:99–112. doi:10.18601/01236458.n55.09. Available from: https://revistas.uexternado.edu.co/index.php/contexto/article/view/7383/10088
Amariles P, Salamanca CH, Moreno CE, Gutiérrez JC, Machado MA. Política industrial farmacéutica, un requisito clave para la autonomía sanitaria de Colombia. Salud UIS [Internet]. 2023;55(1):e23022. doi:10.18273/saluduis.55.e23022. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-08072023000100073
Times of India. ‘Pharmacy of the world’: Over 55 GCCs, 3 lakh jobs—how India is preparing to move up the value chain [Internet]. New Delhi: Times of India; 2025 Sep 19 [cited 2026 Feb 19]. Available from: https://timesofindia.indiatimes.com/city/delhi/pharmacy-of-the-world-over-55-gccs-3-lakh-jobs-how-india-is-preparing-to-move-up-the-value-chain/articleshow/123989076.cms
Fundação Oswaldo Cruz (Fiocruz). Instituto de Tecnologia em Fármacos – Farmanguinhos [Internet]. Rio de Janeiro: Fiocruz; 2026 [cited 2026 Feb 19]. Available from: https://www.gov.br/pt-br/orgaos/fundacao-oswaldo-cruz
Agencia Nacional de Laboratorios Públicos (ANLAP). Carta de referencia al Laboratorio de Hemoderivados de la Universidad Nacional de Córdoba [Internet]. Buenos Aires: Ministerio de Salud y Desarrollo Social de la Nación; 2018 Nov 27 [cited 2026 Feb 19]. Available from: https://publicadministration.un.org/unpsa/Portals/0/UNPSA_Submitted_Docs/2019/A95C2B02-3D64-4775-883B-04C714BF9A89/Carta%20de%20rererencia%20ANLAP.pdf?ver=2018-11-30-113729-047
Government of Vietnam. Decision No. 1165/QD-TTg: National strategy for development of the pharmaceutical industry through 2030, with vision to 2045 [Internet]. Hanoi: Government of Vietnam; 2023 Jul 17 [cited 2026 Feb 19]. Available from: https://english.luatvietnam.vn/y-te/decision-1165-qd-ttg-2023-national-strategy-for-development-of-the-pharmaceutical-industry-through-2030-269422-d1.html
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pedro Amariles, Constain H. Salamanca

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Notice and Open Access Statement
The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.
Authors declare that:
-
They are the intellectual property owners and are responsible for all the information stated in the article.
-
This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.
-
They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.
-
They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.
-
Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.
-
They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.
-
They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.
-
They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.
-
After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.
Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.
